louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00321321: The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes
Official title: Phase 2 Study of The Beta Cell Responsiveness to GIP With and Without Sulfonylurea in Patients With Type 2 Diabetes
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Diabetes Mellitus, Type 2
Keywords: Type 2 diabetes mellitus
Glucose dependent insulinotropic polypeptide
Sulfonylurea compounds
insulin secretion
Sulfonylurea receptor subunit-SUR1
Impaired incretin effect
Lead sponsor: University Hospital, Gentofte, Copenhagen
Sponsor class: OTHER
First posted: 2006-05-03
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: The investigators hypothesize that the impaired insulinotropic effect of the incretin hormone GIP may be due to inadequate sensitization and ATP induced closure of beta cell K-ATP channels. By closing the channels through the use of sulfonylurea (SU) we hope to restore the insulinotropic effect of GIP.


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetes mellitus diagnosed according to WHO criteria
* Diet and/or metformin treatment
* HbA1c \> 7,0% for metformin treated patients
* HbA1c \> 7,5% for diet treated patients
* Age: 18 years or older
* 25 \> BMI \> 40 kg/m2
* Signed informed consent
* Sufficient birth control in case of child bearing capacity

Exclusion Criteria:

* Proliferative retinopathy
* Diabetic nephropathy with s-creatinine \> 130 microM and/or macroalbuminuria
* Liver disease (ALAT \> 2 x normal value)
* CAD (NYHA group III or IV)
* Positive screening for islet-cell and/or GAD-65 autoantibodies
* Type 1 diabetes i first degree relatives
* Gastrointestinal surgery with intestinal resection
* Anemia
* Pregnancy and/or breastfeeding

Primary outcomes:
measure: Insulin Secretion
timeFrame: 0 - 90 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Hellerup, Copenhagen
country: Denmark
facility: Department of Internal Medicine, Gentofte University Hospital
Study officials:
affiliation: Gentofte University Hospital
name: Kasper Aaboe, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT07003321: A Trial of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Official title: Study on Efficacy and Safety of HRS-4508 in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Solid Tumor
Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
Sponsor class: INDUSTRY
First posted: 2025-06-04
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 in subjects with locally advanced or metastatic non-small cell lung cancer; Evaluate the pharmacokinetic (PK) characteristics of HRS-4508 and other efficacy endpoints for the treatment of locally advanced or metastatic non-small cell lung cancer.


Eligibility criteria: Inclusion Criteria:

1. Age: 18 to 80 years old; Both men and women are welcome;
2. Locally advanced or metastatic non-small cell lung cancer that has failed standard treatment or cannot tolerate standard treatment regimens.
3. ECOG ratings of 0 or 1.
4. Expected survival period ≥ 12 weeks.
5. At least one measurable lesion outside the central nervous system that meets the RECIST v1.1 standard definition.
6. Willing to participate and comply with the requirements of the research protocol, and willing to cooperate with follow-up visits.

Exclusion Criteria:

1. Accompanied by untreated or active central nervous system (CNS) tumor metastasis. Subjects with a history of meningeal metastasis or current meningeal metastasis
2. There have been significant severe infections and major surgeries in the past 4 weeks
3. Existence of previous or concurrent malignant tumors
4. Difficult to treat nausea, vomiting, or other gastrointestinal diseases that affect the use of oral medication
5. Having undergone major surgeries other than diagnosis or biopsy within 28 days prior to the first administration; Experiencing traumatic minor surgery within 7 days prior to the first administration of medication

Primary outcomes:
measure: The incidence and severity of adverse events (AE)/serious adverse events (SAE) (rated based on CTCAE v5.0)
timeFrame: 2 years
measure: Objective response rate (ORR)
timeFrame: 1 year
Secondary outcomes:
measure: Blood concentrations of HRS-4508
timeFrame: 12 weeks
measure: Duration of response (DoR)
timeFrame: 1 year
measure: Disease control rate (DCR)
timeFrame: 1 year
measure: Progression free survival (PFS)
timeFrame: 1 year
measure: Overall survival (OS)
timeFrame: 2 years
Other outcomes:
Locations:
city: Shanghai
country: China
facility: Shanghai Pulmonary Hospital
state: Shanghai
Study officials:
References:
Clinical trial NCT01516021: How Fat Influences the Brain
Official title: Fat Intake Modulates Cerebral Blood Flow in Homeostatic and Gustatory Brain Areas in Humans
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Fat Processing in the Brain
Keywords: Fat ingestion
hypothalamus
insula
fMRI
CBF
Lead sponsor: University Hospital Tuebingen
Sponsor class: OTHER
Collaborators: name: German Research Foundation
name: German Federation of Industrial Research Associations
name: Zentrum für Ernährungsmedizin und Prävention
name: German Center for Diabetes Research
name: University of Hohenheim
First posted: 2012-01-24
Enrollment: 11
Sex: MALE
Minimum age (years): 25
Maximum age (years): 32
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The aim of the current study was to investigate the effect of a high versus a low fat meal (operationalized by high and low fat yoghurt) on homeostatic and gustatory brain regions.


Eligibility criteria: Inclusion Criteria:

* male
* healthy

Exclusion Criteria:

* lactose intolerance
* fMRI contraindications (metal implants,...)

Primary outcomes:
measure: Changes in Cerebral Blood Flow due to the high or low fat yoghurt intake after 30 minutes and 120 minutes compared to a baseline measurement 30 minutes before yoghurt intake.
timeFrame: 30 minutes before as well as 30 minutes and 120 minutes after fat intake
Secondary outcomes:
Other outcomes:
Locations:
city: Tuebingen
country: Germany
facility: University Clinic of Tuebingen, MEG Center
Study officials:
References:
citation: Frank S, Linder K, Kullmann S, Heni M, Ketterer C, Cavusoglu M, Krzeminski A, Fritsche A, Haring HU, Preissl H, Hinrichs J, Veit R. Fat intake modulates cerebral blood flow in homeostatic and gustatory brain areas in humans. Am J Clin Nutr. 2012 Jun;95(6):1342-9. doi: 10.3945/ajcn.111.031492. Epub 2012 May 9.
Clinical trial NCT01123421: Develop and Validate Ultrasonic Device for Osteoporotic Fracture Risk Assessment
Official title: Portable Ultrasonometer for Osteoporosis Assessment: Retrospective Fracture Risk Validation Study, Version #1
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Osteoporosis
Fracture
Aging
Keywords: osteoporosis
fracture risk
aging
tibia
sonometer
ultrasound
BMD
bone mineral density
DXA
3D-HRpQT
waveform profiles
Lead sponsor: Artann Laboratories
Sponsor class: INDUSTRY
Collaborators: name: National Institutes of Health (NIH)
name: National Institute on Aging (NIA)
name: Mayo Clinic
First posted: 2010-05-14
Enrollment: 113
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Both groups

Brief summary: Study to demonstrate that the Bone UltraSonic Scanner (BUSS) can aid in detection of osteoporosis and predict prevalent osteoporotic fractures. Measurements derived from the BUSS parameters will be able to discriminate between postmenopausal women with osteoporotic fractures when compared to matched controls without history of osteoporotic fracture.

Detailed description: One of several studies to develop and clinically validate a novel ultrasonographic device, BUSS, for the assessment of osteoporosis and fracture risk.

Eligibility criteria: Inclusion Criteria:

* postmenopausal women with osteoporotic fracture at spine or wrist
* postmenopausal women no history of fracture at spine or wrist

Exclusion Criteria:

* women with a history of metabolic disease
* stroke
* tibia fracture or surgery
* BMI ≥ 35 kg/m2
* Teriparatide use currently or within the past 6 months,
* Any skin issues (open wounds or rashes, and/or skin infections) of the tibial area.

Primary outcomes:
measure: Determine whether BUSS testing is equivalent or superior to DXA for fracture risk assessment in postmenopausal women.
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic Rochester
state: Minnesota
Study officials:
affiliation: Artann Laboratories, Inc.
name: Armen Sarvazyan, Ph.D., D.Sc.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00245921: Study Evaluating Levonorgestrel and Ethinyl Estradiol for Oral Contraception
Official title: A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Efficacy of Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg in a Continuous Daily Regimen for Oral Contraception
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Contraception
Keywords: contraception
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Sponsor class: INDUSTRY
First posted: 2005-10-28
Enrollment: 2000
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 49
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP

Brief summary: To evaluate the safety and contraceptive efficacy of an oral contraceptive containing a combination of LNG 90 mg/EE 20 mg in a continuous-use regimen.


Eligibility criteria: Inclusion Criteria:

* Healthy women aged 18 to 49 years
* Regular (21- to 35- day) menstrual cycles for the 3-month period preceding visit 1
* Must be sexually active and at risk for becoming pregnant.

Exclusion Criteria:

* Planned use of any other form of birth control other than the test article.
* Depression requiring hospitalization or associated with suicidal ideation within the last 3 years.
* High blood pressure (defined as elevated sitting blood pressure: \> 140/90 mm Hg).

Primary outcomes:
measure: To evaluate safety and contraceptive efficacy
Secondary outcomes:
measure: To evaluate the effects of this LNG/EE combination on bleeding profile, endometrial histology, hemostasis measures, hemoglobin levels, discontinuation rates, subject satisfaction, and cycle-related symptoms and work productivity at baseline.
Other outcomes:
Locations:
Study officials:
affiliation: Wyeth is now a wholly owned subsidiary of Pfizer
name: Medical Monitor
role: STUDY_DIRECTOR
References:
citation: Reid RL, Fortier MP, Smith L, Mirkin S, Grubb GS, Constantine GD. Safety and bleeding profile of continuous levonorgestrel 90 mcg/ethinyl estradiol 20 mcg based on 2 years of clinical trial data in Canada. Contraception. 2010 Dec;82(6):497-502. doi: 10.1016/j.contraception.2010.06.002. Epub 2010 Jul 16.
Clinical trial NCT07025421: The ARISE Study - Use of Vertical Positioning
Official title: The Arise Study - Use of Vertical Positioning
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Acute Respiratory Distress Syndrome
Keywords: Bed Position
Lead sponsor: University of Alabama at Birmingham
Sponsor class: OTHER
First posted: 2025-06-17
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The pilot study will randomize 40 ARDS patients who if proning were required would be randomized to upright bed positioning or to stand of care with bed in the head of bed elevation position

Detailed description: Patients will be randomized to receive either daily upright bed positioning or to receive standard of care with head of bed elevated.

Eligibility criteria: Inclusion Criteria:

- Acute Respiratory Distress Syndrome

Exclusion Criteria:

* Cancer
* Active tracheostomy

Primary outcomes:
measure: Change in Tidal Volume
timeFrame: within first 7 days of mechanical ventilation
Secondary outcomes:
Other outcomes:
Locations:
city: Birmingham
country: United States
facility: University of Alabama at Birmingham
state: Alabama
Study officials:
References:
Clinical trial NCT04134221: Internal Carotid Artery Blood Flow in Pediatric Moyamoya Patients
Official title: A Study on Internal Carotid Artery Blood Flow Velocity in Children With Moyamoya Disease Undergoing Surgery: a Prospective Observational Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Carotid Artery, Internal
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2019-10-22
Enrollment: 30
Sex: ALL
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: pediatric Moyamoya disease patients

Brief summary: Little is known about how general anesthesia-induced decrease in cerebral blood flow in pediatric moyamoya pateints. We investigated this question in patients undergoing moyamoya surgery, hypothesizing that cardiorespiratory changes during this procedure would reduce cerebral perfusion.


Eligibility criteria: Inclusion Criteria:

* pediatric patients undergoing encephaloduroarteriosynangiosis surgery for moyamoya disease

Exclusion Criteria:

* cutaneous lesion on the neck

Primary outcomes:
measure: Internal carotid artery blood flow velocity
timeFrame: from anesthetic induction to end of surgery, an average of 5 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Hee-Soo Kim
state: Soul-t'ukpyolsi
Study officials:
References:
Clinical trial NCT03560921: Urinary NGAL Acute Kidney Injury After Stored Red Blood Cells Transfusion in Critically Ill Patients.
Official title: The Association of NGAL With the Development of Acute Kidney Injury After Stored Red Blood Cells Transfusion in Critically Ill Patients.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Kidney Injury
Anemia
Keywords: biomarkers
Lead sponsor: Kasr El Aini Hospital
Sponsor class: OTHER
First posted: 2018-06-18
Enrollment: 147
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult patients admitted to ICU of any age and sex

Brief summary: The study aims to explore the association of the novel urinary bio marker NGAL with the age of PRBCs(packed red blood cells) transfusion in critically ill patients.

Detailed description: The investigators will measure the urinary NGAL in all patients who received blood transfusion in the intensive care unit during the study period. The age of PRBCs transfusion will be correlated with the incidence of AKI. The rise of NGAL and serum creatinine will be used to diagnose AKI (Acute Kidney Injury).

Eligibility criteria: Inclusion Criteria:

* Any patients admitted to the intensive care unit.

Exclusion Criteria:

* patients who have established AKI at the time of recruitment

Primary outcomes:
measure: Incidence of AKI
timeFrame: within 30 days
Secondary outcomes:
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Cairo university hospitals
Study officials:
affiliation: faculty of medicine-Cairo University Hospitals
name: Tarek Abdelaziz
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04587921: Feasibility and Impact of Remote Oximetry in Patients Hospitalized With Covid-19
Official title: Feasibility and Impact of Remote Oximetry and Cardiac Frequency Monitoring in Patients Hospitalized and Isolated With Covid-19
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Oximetry
Covid19
Lead sponsor: University of Sao Paulo General Hospital
Sponsor class: OTHER
First posted: 2020-10-14
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: SUPPORTIVE_CARE

Brief summary: The objective of MoxiCov is to monitor the oximetry of patients admitted to the Covid nursery to provide a more detailed assistance expecting to reduce the amount of hypoxia in these patients.


Eligibility criteria: Inclusion Criteria:

* Over 18 years old
* COVID 19 positive or suspected COVID19

Primary outcomes:
measure: Feasibility of the system: Determination of the number of valid versus not valid or missed measurements
timeFrame: 6 months
measure: Hypoxic burden
timeFrame: 6 months
measure: Hypoxic alarm
timeFrame: 6 months
measure: Satisfaction of the nursing, medical team and patients with the implemented system
timeFrame: 6 months
Secondary outcomes:
measure: Time of SpO2<90%, SpO2<85% and SpO2<80%
timeFrame: 6 months
measure: Number of false alarms caused by malfunctions or bad oximeter positioning
timeFrame: 6 months
measure: Total hospital stay
timeFrame: 6 months
measure: Time of supplementary oxygen use
timeFrame: 6 months
measure: Mortality of participants
timeFrame: 6 months
Other outcomes:
Locations:
city: São Paulo
country: Brazil
facility: Fundação Zerbini - Instituto do Coração (InCor)
state: SP
Study officials:
References:
Clinical trial NCT05357521: Interplay Between Oxytocin and Cortisol During Stress in Borderline Personality Disorder
Official title: Feasibility and Preliminary Data on the Interplay Between Oxytocin and Cortisol During Stress in Borderline Personality Disorder
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Borderline Personality Disorder
Oxytocin
Keywords: cortisol
tsst
borderline personnality
stress
Lead sponsor: University of Geneva, Switzerland
Sponsor class: OTHER
First posted: 2022-05-03
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Participants with and without borderline personality disorder

Brief summary: This study aims to determine the feasibility and preliminary data on the interaction between oxytocin and cortisol during stress in borderline personnality disorder.

Detailed description: The investigators will recruit 50 female patients with borderline personnality disorder and 50 controls with no psychiatric diagnosis, aged between 18 and 25 years old.

salivary cortisol daily curve ( 6 measures during the day) will be measured in participant's naturalistic environnement, together with salivary oxytocin. In addition, salivary oxytocin and cortisol will be measured during a psychosocial stress task and recovery.

Eligibility criteria: Inclusion Criteria:

* Borderline personality disorder-DSM V

Exclusion Criteria:

* Schizophrenia

Primary outcomes:
measure: Salivary cortisol
timeFrame: Baseline
measure: Salivary cortisol
timeFrame: Change in one day (circadian cortisol with 6 measures within one day
measure: Salivary cortisol
timeFrame: Change during experimental task (up to 2 hours)
measure: Salivary oxytocin
timeFrame: Baseline
measure: Salivary oxytocin
timeFrame: Two measures within one day
measure: Salivary oxytocin
timeFrame: Change during experimental task (up to 2 hours)
Secondary outcomes:
Other outcomes:
Locations:
city: Geneva
country: Switzerland
facility: Young Adult Psychiatric Unit
Study officials:
affiliation: Geneva Univeristy hospital
name: Tatiana Aboulafia Brakha, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00395564: Chart Review of Those Who Have Had Open, Laparoscopic, Ureteroscopic, or Percutaneous Surgery
Official title: Retrospective Chart Review of Patients Who Have Had an Open, Laparoscopic, Ureteroscopic or Percutaneous Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Urologic Diseases
Keywords: Urologic Surgery
Lead sponsor: University of California, Irvine
Sponsor class: OTHER
First posted: 2006-11-03
Enrollment: 150
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Those who have urologic conditions that need to be treated with open, laparoscopic, ureteroscopic, or percutaneous urologic surgery.

Brief summary: The investigator intends to review retrospective de-identified data of patients who have had Open, Laparoscopic, Ureteroscopic or Percutaneous Urologic Surgery.

Detailed description: The investigator reviews retrospective de-identified data of patients who have had Open, Laparoscopic, Ureteroscopic or Percutaneous Urologic Surgery in order to determine different clinical or operative issues.

Eligibility criteria: Inclusion Criteria:

* Patients must have had Open, Laparoscopic, Ureteroscopic or Percutaneous Urologic Surgery at UCIMC Department of Urology

Primary outcomes:
measure: Develop outcome effectiveness for minimally invasive procedures
timeFrame: December 2015
Secondary outcomes:
Other outcomes:
Locations:
city: Orange
country: United States
facility: University of California, Irvine Medical Center
state: California
Study officials:
affiliation: University of California Irvine-Department of Urology
name: Elspeth McDougall
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03038464: Synovial Aspiration and Serological Testing in Two-stage Revision Arthroplasty of Prosthetic Joint Infection
Official title: Benefit of Synovial Aspiration and Serological Testing in Two-stage Revision Arthroplasty of Prosthetic Joint Infection
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Diagnosis Prosthetic Joint Infection
Lead sponsor: Technical University of Munich
Sponsor class: OTHER
First posted: 2017-01-31
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with periprostheitc joint infection

Brief summary: The two-stage protocol is gold standard in terms of infection control treating prosthetic joint infections of total hip and total knee arthroplasty. The antibiotic pause for diagnostic reasons before reconstruction (stage two) is discussed concerning persistence of infection and development of resistant bacterial strains. Serological markers and synovial analysis are common use to exclude persistence of infection.

The investigators therefore asked 1) is the serological testing of c-reactive protein and leukocytes a valuable tool to predict a persistence of infection and 2) what is the role of synovial aspiration of PMMA Spacers on hip and knee joints.


Eligibility criteria: Inclusion Criteria:

* Patients with periprostheitc joint infection

Exclusion Criteria:

* Reinfection in history

Primary outcomes:
measure: Reinfection rate
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
city: Munich
country: Germany
facility: Klinikum rechts der Isar
state: Bavaria
Study officials:
References: